Variables | Univariate analysis | Multivariable analysis - model 1 a | Multivariable analysis - model 2 a | |||
---|---|---|---|---|---|---|
HR [95% CI] | P value | HR [95% CI] | P value | HR [95% CI] | P value | |
Afatinib dose (40 mg daily vs. 30 mg daily) | 0.86 [0.58–1.29] | 0.4657 |  |  |  |  |
Sex (male vs. female) | 1.19 [0.80–1.79] | 0.3920 |  |  |  |  |
Age (≥65 vs. < 65) | 0.79 [0.53–1.17] | 0.2333 |  |  |  |  |
Smoking history (ever smokers vs. never smokers) | 1.16 [0.71–1.89] | 0.5659 |  |  |  |  |
ECOG (≥2 vs. ≤1) | 1.11 [0.67–1.84] | 0.6762 |  |  |  |  |
Exon 21 vs. exon 19 b | 1.31 [0.89–1.95] | 0.1751 |  |  | 1.56 [1.04–2.36] | 0.0336 |
Number of metastatic sites/organs (1–2 vs. ≥3) | 1.86 [1.20–2.88] | 0.0055 | 1.83 [1.19–2.84] | 0.0065 |  |  |
Metastatic site/organ on initial diagnosis: (yes vs. no) | ||||||
 Brain | 0.96 [0.62–1.49] | 0.8479 |  |  |  |  |
 Lung | 0.96 [0.64–1.44] | 0.8318 |  |  |  |  |
 Pleura (or with pleural effusion) | 1.57 [1.05–2.35] | 0.0292 |  |  | 1.77 [1.17–2.69] | 0.0075 |
 Bone | 1.52 [1.02–2.27] | 0.0385 |  |  | 1.69 [1.13–2.55] | 0.0116 |
 Liver | 1.50 [0.89–2.54] | 0.1266 |  |  |  |  |
 Adrenal gland | 0.96 [0.50–1.84] | 0.8955 |  |  |  |  |
 Other site | 0.84 [0.34–2.07] | 0.7055 |  |  |  |  |
Dose reduction (yes vs. no) | 0.56 [0.32–0.98] | 0.0407 | 0.57 [0.33–0.99] | 0.0467 | 0.59 [0.34–1.03] | 0.0640 |